Mark Wildgust, VP on SPARTAN and TITAN Studies: What Does This Mean for Cancer Care? @JanssenGlobal #ASCO @JanssenUS #ASCO2020

Mark Wildgust, VP of Janssen @JanssenUS discusses ERLEADA (apalutamide) significantly improving overall survival in patients with non-metastatic castration-resistant prostate cancer: phase 3 SPARTAN study final results.

Read here: https://meetinglibrary.asco.org/record/187437/abstract